Cobalt MRI CRT-D (DTPB2D1, DTPB2D4, DTPB2Q1, DTPB2QQ); Cobalt XT MRI CRT-D (DTPA2D1, DTPA2D4, DTPA2Q1, DTPA2QQ); Crome M
Medtronic Cardiac Rhythm Disease Management · Decision date Nov 4, 2026
What did the FDA approve?
FDA records P010031/S931 as a supplement to PMA P010031, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Nov 4, 2026.
FDA approval order statement
approval for device labeling updates and change to nominal settings for Intrinsic Antitachycardia Pacing (iATP) feature in applicable Cobalt devices
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 4, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P010031/S931
- Regulatory pathway
- PMA supplement
- Product code
- NIK
- Decision code
- APPR
- Decision date
- Nov 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D).
- Product code
- NIK
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P010031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010031 · Original PMA
CONCERTO/INSYNC SENTRY/INSYNC MAXIMO IMPLANTABLE CARDIOVASCULAR DEFIBRILLATORS WITH CARDIAC RESYNCHICNIZATION
P010031/S931 received
Application receipt date recorded by FDA.
P010031/S932 · Related supplement
Cobalt MRI CRT-D, Cobalt XT MRI CRT-D, Crome MRI CRT-D
P010031/S933 · Related supplement
Cobalt MRI CRT-D (DTPB2Dl, DTPB2D4, DTPB2Ql, DTPB2QQ); Cobalt XT MRI CRT-D (DTPA2Dl, DTPA2D4, DTPA2Ql, DTPA2QQ); Crome M
P010031/S934 · Related supplement
Cobalt MRI CRT-D, Cobalt XT MRI CRT-D, Crome MRI CRT-D
P010031/S931 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P010031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Cardiac Rhythm Disease Management | PMA approval | Jun 26, 2002 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Sep 25, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Cardiac Rhythm Disease Management
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P010031/S931
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


